non-AIDS defining cancers (NADCs) among aging HIV+ individuals

老年艾滋病毒感染者中的非艾滋病定义癌症（NADC）

• 批准号: 10249743
• 负责人: ROBERT H VONDERHEIDE
• 金额: $ 7.93万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-12-01 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10249743
• 关键词: Address; Adoptive Immunotherapy; African; Aging; Basic Science; Behavior; Biology; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Catchment Area; Cause of Death; Clinical; Clinical Research; Clinical Sciences; Communities; Complex; County; Cutaneous; Delaware; Detection; Diagnosis; Education and Outreach; Environmental Impact; Fostering; Genetic; Genomics; Goals; Grant; HIV; Health; Immunotherapy; Individual; Informatics; Infusion procedures; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Mesothelioma; Molecular; Molecular Epidemiology of Cancer; New Jersey; Obesity; Patients; Pediatric Hospitals; Pennsylvania; Philadelphia; Population Research; Population Sciences; Positioning Attribute; Prevention; Research; Resistance; Resources; Scientist; Skin tanning; Smoking; Statutes and Laws; Sun Exposure; Toxic Environmental Substances; Toxicology; Translations; United States; Universities; University Hospitals; behavior change; brain behavior; cancer care; cancer epidemiology; cancer therapy; cancer type; checkpoint therapy; clinical practice; cognitive neuroscience; environmental carcinogenesis; epigenomics; ethnic diversity; innovation; malignant breast neoplasm; melanoma; member; molecular imaging; novel; outreach program; patient oriented; personalized diagnostics; personalized medicine; precision oncology; prevent; programs; rare cancer; recruit; targeted treatment; therapy development; therapy resistant; tool; trait; tumor; tumor metabolism; vaccine development

The goal of the Abramson Cancer Center (ACC) of the University of Pennsylvania is to bring together more than 310 members to transform the paradigm of patient-centered cancer care and cancer control by integrating high impact Programs of basic, clinical, and population-based research, fostering pioneering scientific discoveries, and facilitating the translation of these discoveries into clinical practice. In doing so, the ACC builds upon the great clinical cancer care at renowned hospitals of the University of Pennsylvania and the Children’s Hospital of the Philadelphia. The ACC continues to build on its significant historical strengths in basic cancer biology, translational immunotherapy, and population science research. By leveraging the infusion of new Institutional resources and significant philanthropic resources, the ACC will continue to innovate to reduce the burden of cancer in our catchment area during the next project period and will seek to: (1) Accelerate and expand its leadership in adoptive cellular immunotherapy, combination immune checkpoint therapies, and vaccine development for both prevention and treatment of cancers. (2) Increase translation of cancer basic biology through the philanthropic and Institutionally supported ACC Translational Centers of Excellence that integrate basic, translational and clinical scientists from the ACC Programs to impact on the prevention, detection, and treatment of specific types of cancers that afflict our catchment area. (3) Accelerate precision cancer medicine through novel Molecular Imaging, the Center for Personalized Diagnostics, the Molecular Tumor Board, and the Circulating Tumor Material Developing Core, which were implemented in the past project period, and the implementation of the Center for Rare Cancers and Personalized Therapy in the next project period. (4) Innovate means to understand, prevent, and treat therapy-resistant cancers by incorporating genomics, epigenomics, informatics and research in cancer metabolism, which is frequently re-wired in resistance to targeted therapies. (5) Lead population-based research through recruitment and research tools in genetics and complex traits with an emphasis on cancer epidemiology. Implement projects in cancer molecular epidemiology among patients of African descent and accelerate our Outreach Program to increase research relevant to our catchment area. (6) Launch a new Brain and Behavior Change initiative and harness new tools from cognitive neurosciences to control cancer by modulating behaviors that predispose to smoking or contribute to obesity. Lead in Toxicology and Environmental Carcinogenesis to understand environmental toxins and impact the health of patients with mesothelioma in our catchment area.

宾夕法尼亚大学艾布拉姆森癌症中心 (ACC) 的目标是汇集更多 超过 310 名成员通过整合来改变以患者为中心的癌症护理和癌症控制的范式 高影响力的基础、临床和人群研究计划，培育开拓性科学 ACC 致力于发现这些发现，并促进将这些发现转化为临床实践。 建立在宾夕法尼亚大学和美国著名医院出色的临床癌症护理基础上 费城儿童医院继续发挥其重要的历史优势。 基础癌症生物学、转化免疫疗法和人口科学研究。 注入新的机构资源和重要的慈善资源，ACC 将继续 在下一个项目期间进行创新，以减轻我们学区的癌症负担，并将寻求： （1）加速并扩大其在过继性细胞免疫治疗、联合免疫治疗领域的领先地位 用于预防和治疗癌症的检查点疗法和疫苗开发。 (2) 通过慈善和机构支持的 ACC 增加癌症基础生物学的翻译 卓越转化中心整合了 ACC 的基础科学家、转化科学家和临床科学家 影响我们的特定类型癌症的预防、检测和治疗的计划 集水区。 (3) 通过新型分子成像、个性化中心加速精准癌症医学 诊断、分子肿瘤板和循环肿瘤材料开发核心，其中 在过去的项目期间实施了，以及罕见癌症中心和 下一个项目期间的个性化治疗。 (4) 创新手段通过结合基因组学来理解、预防和治疗难治性癌症， 表观基因组学、信息学和癌症代谢研究，经常被重新连接以抵抗 靶向治疗。 (5) 通过遗传学和复杂性状的招募和研究工具领导基于人群的研究 重点是癌症流行病学。实施癌症分子流行病学项目。 非洲人后裔患者并加速我们的外展计划，以增加与我们的相关研究 集水区。 (6) 启动新的大脑和行为改变计划并利用认知神经科学的新工具 通过调节易吸烟或导致肥胖的行为来控制癌症。 毒理学和环境致癌作用，了解环境毒素及其对健康的影响 我们学区的间皮瘤患者。